Human immunodeficiency virus type 1 Group-specific antigen polyprotein conserved epitopes (HIV-1 Gag conserved epitopes)

HIV-1 Gag conserved epitopes are highly stable peptide sequences within the Group-specific antigen (Gag) polyprotein of the Human Immunodeficiency Virus type 1. The Gag polyprotein is a critical structural component responsible for orchestrating the assembly, budding, and maturation of new viral particles, comprising subunits such as matrix (p17), capsid (p24), and nucleocapsid (p7) (UniProt P03367). Because these specific epitopes are located in regions essential for viral fitness, they are less prone to the rapid mutation and immune escape characteristic of other HIV-1 proteins (Mothe et al., 2012, PubMed: 22531595). Consequently, they serve as primary targets for the development of universal T-cell vaccines and immunotherapies designed to elicit broad and potent CD8+ and CD4+ T-cell responses (Hanke, 2019, PubMed: 30714104). By directing the immune system to recognize these conserved segments, researchers aim to control viral replication across diverse HIV-1 clades and potentially contribute to a functional cure. Clinical strategies often utilize viral vectors or DNA platforms to deliver these immunogens, such as the HTI or HIVconsv constructs, to patients (ClinicalTrials.gov: NCT03204617).

Other names

HIV-1 Gag conserved regionsGag-specific T-cell epitopesHIV-1 Gag polyprotein epitopesConserved Gag peptidesHIV-1 Gag p55 epitopes

Induction of broad and potent CD8+ cytotoxic T-lymphocyte (CTL) and CD4+ T-helper cell responses against functionally constrained viral regions to inhibit replication and prevent immune escape.